High-fat diet induces significant metabolic disorders in a mouse model of polycystic ovary Syndrome

Biology of Reproduction

Volumn 91, Issue 5, 2014, Pages

  Lai, Hao ^a   Jia, Xiao ^a   Yu, Qiuxiao ^a   Zhang, Chenglu ^a   Qiao, Jie ^b   Guan, Youfei ^a   Kang, Jihong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PRASTERONE; SESAME SEED OIL; TESTOSTERONE;

ABDOMINAL FAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ESTRUS CYCLE; FATTY LIVER; FEMALE; GLUCOSE INTOLERANCE; LIPID DIET; METABOLIC BALANCE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PREPUBERTY; PRIORITY JOURNAL; REPRODUCTION; SKELETAL MUSCLE; ADVERSE EFFECTS; ANIMAL; BLOOD; BODY COMPOSITION; BODY WEIGHT; C57BL MOUSE; COMPLICATION; DISEASE MODEL; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLIC DISEASES; METABOLISM; OVARY; PATHOLOGY; PHYSIOLOGY;

MUS; SESAMUM INDICUM;

ANIMALS; BODY COMPOSITION; BODY WEIGHT; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ESTROUS CYCLE; FEMALE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLIC DISEASES; MICE; MICE, INBRED C57BL; OVARY; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE;

EID: 84929147396     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.114.120063     Document Type: Article

References (45)

1. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011; 7:219-231.
2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333:853-861.
3. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012; 33:981-1030.
4. Escobar-Morreale HF. Surgical management of metabolic dysfunction in PCOS. Steroids 2012; 77:312-316.
5. Manneras-Holm L, Leonhardt H, Kullberg J, Jennische E, Oden A, Holm G, Hellstrom M, Lonn L, Olivecrona G, Stener-Victorin E, Lonn M. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 2011; 96:E304-E311.
6. Borruel S, Fernandez-Duran E, Alpanes M, Marti D, Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF. Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 2013; 98:1254-1263.
7. Karoli R, Fatima J, Chandra A, Gupta U, Islam FU, Singh G. Prevalence of hepatic steatosis in women with polycystic ovary syndrome. J Hum Reprod Sci 2013; 6:9-14.
8. Ward RC, Costoff A, Mahesh VB. The induction of polycystic ovaries in mature cycling rats by the administration of dehydroepiandrosterone (DHA). Biol Reprod 1978; 18:614-623.
9. Roy S, Mahesh VB, Greenblatt RB. Effect of dehydroepiandrosterone and delta4-androstenedione on the reproductive organs of female rats: production of cystic changes in the ovary. Nature 1962; 196:42-43.
10. Sander V, Luchetti CG, Solano ME, Elia E, Di Girolamo G, Gonzalez C, Motta AB. Role of the N, N'-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. Reproduction 2006; 131:591-602.
11. Lee MT, Anderson E, Lee GY. Changes in ovarian morphology and serum hormones in the rat after treatment with dehydroepiandrosterone. Anat Rec 1991; 231:185-192.
12. Anderson E, Lee MT, Lee GY. Cystogenesis of the ovarian antral follicle of the rat: ultrastructural changes and hormonal profile following the administration of dehydroepiandrosterone. Anat Rec 1992; 234:359-382.
13. Dowling AR, Nedorezov LB, Qiu X, Marino JS, Hill JW. Genetic factors modulate the impact of pubertal androgen excess on insulin sensitivity and fertility. PLoS One 2013; 8:e79849.
14. Luchetti CG, Solano ME, Sander V, Arcos ML, Gonzalez C, Di Girolamo G, Chiocchio S, Cremaschi G, Motta AB. Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function. J Reprod Immunol 2004; 64:59-74.
15. Brothers KJ, Wu S, DiVall SA, Messmer MR, Kahn CR, Miller RS, Radovick S, Wondisford FE, Wolfe A. Rescue of obesity-induced infertility in female mice due to a pituitary-specific knockout of the insulin receptor. Cell Metab 2010; 12:295-305.
16. Manneras L, Cajander S, Holmang A, Seleskovic Z, Lystig T, Lonn M, Stener-Victorin E. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology 2007; 148: 3781-3791.
17. Zhang Y, Gan Z, Huang P, Zhou L, Mao T, Shao M, Jiang X, Chen Y, Ying H, Cao M, Li J, Zhang WJ, et al. A role for protein inhibitor of activated STAT1 (PIAS1) in lipogenic regulation through SUMOylationindependent suppression of liver X receptors. J Biol Chem 2012; 287: 37973-37985.
18. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, Guertin DA, Madden KL, Carpenter AE, Finck BN, Sabatini DM. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011; 146:408-420.
19. Hasegawa S, Noda K, Maeda A, Matsuoka M, Yamasaki M, Fukui T. Acetoacetyl-CoA synthetase, a ketone body-utilizing enzyme, is controlled by SREBP-2 and affects serum cholesterol levels. Mol Genet Metab 2012; 107:553-560.
20. Wang Q, Li S, Jiang L, Zhou Y, Li Z, Shao M, Li W, Liu Y. Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice. J Lipid Res 2010; 51:2516-2526.
21. Chen L, Miao Y, Zhang Y, Dou D, Liu L, Tian X, Yang G, Pu D, Zhang X, Kang J, Gao Y, Wang S, et al. Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility. Arterioscler Thromb Vasc Biol 2012; 32:3024-3032.
22. Kang J, Chapdelaine P, Laberge PY, Fortier MA. Functional characterization of prostaglandin transporter and terminal prostaglandin synthases during decidualization of human endometrial stromal cells. Hum Reprod 2006; 21:592-599.
23. Kang J, Chapdelaine P, Parent J, Madore E, Laberge PY, Fortier MA. Expression of human prostaglandin transporter in the human endometrium across the menstrual cycle. J Clin Endocrinol Metab 2005; 90:2308-2313.
24. Marino JS, Iler J, Dowling AR, Chua S, Bruning JC, Coppari R, Hill JW. Adipocyte dysfunction in a mouse model of polycystic ovary syndrome (PCOS): evidence of adipocyte hypertrophy and tissue-specific inflammation. PLoS One 2012; 7:e48643.
25. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 46:2347-2355.
26. Shi D, Vine DF. Animal models of polycystic ovary syndrome: a focusedreview of rodent models in relationship to clinical phenotypes and cardiometabolic risk. Fertil Steril 2012; 98:185-193.
27. Walters KA, Allan CM, Handelsman DJ. Rodent models for human polycystic ovary syndrome. Biol Reprod 2012; 86:149, 1-12.
28. Padmanabhan V, Veiga-Lopez A. Animal models of the polycystic ovary syndrome phenotype. Steroids 2013; 78:734-740.
29. van Houten EL, Kramer P, McLuskey A, Karels B, Themmen AP, Visser JA. Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology 2012; 153:2861-2869.
30. Tortoriello DV, McMinn J, Chua SC. Dietary-induced obesity and hypothalamic infertility in female DBA/2J mice. Endocrinology 2004; 145:1238-1247.
31. Wu S, Divall S, Nwaopara A, Radovick S, Wondisford F, Ko C, Wolfe A. Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes 2014; 63:1270-1282.
32. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002; 26: 883-896.
33. Salehi M, Bravo-Vera R, Sheikh A, Gouller A, Poretsky L. Pathogenesis of polycystic ovary syndrome: what is the role of obesity? Metabolism 2004; 53:358-376.
34. Yen TT, Allan JA, Pearson DV, Acton JM, Greenberg MM. Prevention of obesity in Avy/a mice by dehydroepiandrosterone. Lipids 1977; 12: 409-413.
35. Gomez-Santos C, Larque E, Granero E, Hernandez-Morante JJ, Garaulet M. Dehydroepiandrosterone-sulphate replacement improves the human plasma fatty acid profile in plasma of obese women. Steroids 2011; 76: 1425-1432.
36. Lafontan M. Adipose tissue and adipocyte dysregulation. Diabetes Metab 2014; 40:16-28.
37. Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone. Lancet 1994; 343:1479-1481.
38. Palomba S, Falbo A, Zullo F, Orio F, Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009; 30:1-50.
39. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111:607-613.
40. Zhao Y, Fu L, Li R, Wang LN, Yang Y, Liu NN, Zhang CM, Wang Y, Liu P, Tu BB, Zhang X, Qiao J. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Med 2012; 10:153.
41. Sun L, Hu W, Liu Q, Hao Q, Sun B, Zhang Q, Mao S, Qiao J, Yan X. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Proteome Res 2012; 11:2937-2946.
42. Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu D, Gao X. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res 2010; 51:2504-2515.
43. Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, Adams VL, Thomas EL, Bell JD, Kemp GJ, Cuthbertson DJ. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 2012; 97:3709-3716.
44. Michaliszyn SF, Lee S, Tfayli H, Arslanian S. Polycystic ovary syndrome and nonalcoholic fatty liver in obese adolescents: association with metabolic risk profile. Fertil Steril 2013; 100:1745-1751.
45. Hogg K, Wood C, McNeilly AS, Duncan WC. The in utero programming effect of increased maternal androgens and a direct fetal intervention on liver and metabolic function in adult sheep. PLoS One 2011; 6:e24877.